Laura Chico
Stock Analyst at Wedbush
(3.65)
# 807
Out of 5,124 analysts
234
Total ratings
46.63%
Success rate
7.67%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $46 | $36.89 | +24.70% | 11 | Dec 22, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $31 → $30 | $16.02 | +87.27% | 10 | Dec 11, 2025 | |
| VERA Vera Therapeutics | Maintains: Neutral | $23 → $33 | $47.07 | -29.89% | 9 | Dec 11, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $42 → $47 | $30.20 | +55.63% | 8 | Dec 10, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Underperform | $77 → $83 | $276.92 | -70.03% | 9 | Dec 5, 2025 | |
| PHVS Pharvaris | Maintains: Outperform | $27 → $30 | $24.88 | +20.58% | 8 | Nov 13, 2025 | |
| MAZE Maze Therapeutics | Maintains: Outperform | $35 → $36 | $38.63 | -6.81% | 2 | Nov 7, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $35 → $32 | $23.57 | +35.77% | 11 | Nov 7, 2025 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $22 → $32 | $32.55 | -1.69% | 8 | Nov 5, 2025 | |
| ATXS Astria Therapeutics | Downgrades: Neutral | $28 → $13 | $12.82 | +1.40% | 10 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $11 | $3.36 | +227.38% | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $8 | $6.67 | +19.94% | 12 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $18 | $13.12 | +37.20% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $14 | $5.33 | +162.66% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $43 | $41.79 | +2.91% | 9 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $38.11 | -16.03% | 12 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $2.74 | +82.48% | 6 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $14 | $6.09 | +129.89% | 14 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $137 → $141 | $135.99 | +3.68% | 10 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $34 | $23.11 | +47.12% | 13 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $7.41 | +142.91% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $130 | $105.40 | +23.34% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $121 | $174.63 | -30.71% | 18 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $16.53 | -75.80% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $1.66 | +80.72% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $24.87 | +16.61% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $4.08 | +71.57% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.68 | +1,520.03% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $8.69 | -42.46% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $58.87 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $4.89 | +2.25% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $9.93 | +1,395.47% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $7.83 | +9,095.40% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $221.32 | +26.51% | 1 | Apr 21, 2017 |
Dianthus Therapeutics
Dec 22, 2025
Reiterates: Outperform
Price Target: $46
Current: $36.89
Upside: +24.70%
Denali Therapeutics
Dec 11, 2025
Maintains: Outperform
Price Target: $31 → $30
Current: $16.02
Upside: +87.27%
Vera Therapeutics
Dec 11, 2025
Maintains: Neutral
Price Target: $23 → $33
Current: $47.07
Upside: -29.89%
Viridian Therapeutics
Dec 10, 2025
Maintains: Outperform
Price Target: $42 → $47
Current: $30.20
Upside: +55.63%
Praxis Precision Medicines
Dec 5, 2025
Maintains: Underperform
Price Target: $77 → $83
Current: $276.92
Upside: -70.03%
Pharvaris
Nov 13, 2025
Maintains: Outperform
Price Target: $27 → $30
Current: $24.88
Upside: +20.58%
Maze Therapeutics
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $36
Current: $38.63
Upside: -6.81%
Edgewise Therapeutics
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $23.57
Upside: +35.77%
Stoke Therapeutics
Nov 5, 2025
Maintains: Outperform
Price Target: $22 → $32
Current: $32.55
Upside: -1.69%
Astria Therapeutics
Oct 15, 2025
Downgrades: Neutral
Price Target: $28 → $13
Current: $12.82
Upside: +1.40%
Sep 30, 2025
Maintains: Outperform
Price Target: $15 → $11
Current: $3.36
Upside: +227.38%
Sep 30, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $6.67
Upside: +19.94%
Aug 14, 2025
Maintains: Outperform
Price Target: $17 → $18
Current: $13.12
Upside: +37.20%
Aug 13, 2025
Maintains: Outperform
Price Target: $17 → $14
Current: $5.33
Upside: +162.66%
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $41.79
Upside: +2.91%
Aug 7, 2025
Maintains: Outperform
Price Target: $30 → $32
Current: $38.11
Upside: -16.03%
Aug 6, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $2.74
Upside: +82.48%
Aug 5, 2025
Maintains: Outperform
Price Target: $13 → $14
Current: $6.09
Upside: +129.89%
Jul 31, 2025
Maintains: Outperform
Price Target: $137 → $141
Current: $135.99
Upside: +3.68%
Jul 14, 2025
Maintains: Neutral
Price Target: $35 → $34
Current: $23.11
Upside: +47.12%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $7.41
Upside: +142.91%
Jun 18, 2025
Reiterates: Neutral
Price Target: $130
Current: $105.40
Upside: +23.34%
Jun 12, 2025
Reiterates: Neutral
Price Target: $121
Current: $174.63
Upside: -30.71%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $16.53
Upside: -75.80%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $1.66
Upside: +80.72%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $24.87
Upside: +16.61%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $4.08
Upside: +71.57%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.68
Upside: +1,520.03%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $8.69
Upside: -42.46%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $58.87
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $4.89
Upside: +2.25%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $9.93
Upside: +1,395.47%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $7.83
Upside: +9,095.40%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $221.32
Upside: +26.51%